Payment overview · 2025
General Payments
$371.90
16 reported records · 11 companies
Healthcare provider profile · identity verified
Anthony C Stumbo, MD
Allopathic & Osteopathic Physicians|Internal Medicine · PRESTONSBURG, KY · NPI 1780769422
Verified facts
What the public records show
CMS Open Payments records show Anthony C Stumbo, MD received $371.90 in general payments during 2025 across 16 reported records.
Novartis Pharmaceuticals Corporation accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Mounjaro by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $93.61 | 25.2% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $60.43 | 16.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $36.89 | 9.9% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $33.29 | 8.9% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $28.73 | 7.7% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.76 | 6.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $22.02 | 5.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $21.46 | 5.8% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $18.97 | 5.1% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.39 | 4.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.35 | 4.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $326.90 | 15 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $93.61 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $36.89 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $33.29 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $28.73 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $22.02 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $16.35 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $15.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
51 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 476 | 110 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 360 | 54 |
| Gabapentin | Gabapentin | 352 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 305 | 72 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 297 | 72 |
| Atorvastatin Calcium | Atorvastatin Calcium | 283 | 72 |
| Losartan Potassium | Losartan Potassium | 261 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 243 | 62 |
| Omeprazole | Omeprazole | 237 | 53 |
| Metformin Hcl | Metformin Hcl | 190 | 50 |
| Alprazolam | Alprazolam | 189 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 184 | 43 |
| Tramadol Hcl | Tramadol Hcl | 167 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 46 |
| Lisinopril | Lisinopril | 152 | 47 |
| Hydrochlorothiazide | Hydrochlorothiazide | 143 | 36 |
| Furosemide | Furosemide | 132 | 50 |
| Montelukast Sodium | Montelukast Sodium | 130 | 35 |
| Allopurinol | Allopurinol | 127 | 27 |
| Meloxicam | Meloxicam | 125 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 113 | 27 |
| Carvedilol | Carvedilol | 112 | 27 |
| Zolpidem Tartrate | Zolpidem Tartrate | 103 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 102 | 22 |
| Valsartan | Valsartan | 102 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 98 | 22 |
| Citalopram Hbr | Citalopram Hydrobromide | 85 | 19 |
| Pregabalin | Pregabalin | 85 | 20 |
| Escitalopram Oxalate | Escitalopram Oxalate | 83 | 20 |
| Simvastatin | Simvastatin | 82 | 20 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 24 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 79 | 17 |
| Doxycycline Hyclate | Doxycycline Hyclate | 78 | 63 |
| Irbesartan | Irbesartan | 71 | suppressed |
| Potassium Chloride | Potassium Chloride | 68 | 16 |
| Eliquis | Apixaban | 61 | 16 |
| Sertraline Hcl | Sertraline Hcl | 59 | 17 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 56 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 52 | 12 |
| Synthroid | Levothyroxine Sodium | 51 | 14 |
| Tizanidine Hcl | Tizanidine Hcl | 51 | suppressed |
| Januvia | Sitagliptin Phosphate | 49 | 15 |
| Celecoxib | Celecoxib | 48 | 11 |
| Ezetimibe | Ezetimibe | 47 | 14 |
| Glimepiride | Glimepiride | 47 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Diazepam | Diazepam | 43 | suppressed |
| Methylprednisolone | Methylprednisolone | 42 | 39 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 41 | 11 |
| Lansoprazole | Lansoprazole | 39 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 38 | suppressed |
| Finasteride | Finasteride | 38 | suppressed |
| Clonazepam | Clonazepam | 37 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 37 | 13 |
| Gemfibrozil | Gemfibrozil | 37 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 37 | 16 |
| Meclizine Hcl | Meclizine Hcl | 35 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 34 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 34 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 33 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 32 | suppressed |
| Glipizide | Glipizide | 32 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 31 | suppressed |
| Mounjaro | Tirzepatide | 30 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 30 | 24 |
| Atenolol | Atenolol | 29 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 29 | suppressed |
| Famotidine | Famotidine | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 27 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 25 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 21 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Ibuprofen | Ibuprofen | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Glipizide Er | Glipizide | 22 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 20 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Repatha Sureclick | Evolocumab | 20 | suppressed |
| Spironolactone | Spironolactone | 20 | suppressed |
| Glyburide | Glyburide | 19 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Ozempic | Semaglutide | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 16 | suppressed |
| Dutasteride | Dutasteride | 16 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 16 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 16 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Nystatin | Nystatin | 16 | 12 |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Fluconazole | Fluconazole | 15 | 11 |
| Memantine Hcl | Memantine Hcl | 15 | suppressed |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Nifedipine Er | Nifedipine | 15 | suppressed |
| Sotalol | Sotalol Hcl | 15 | suppressed |
| Bupropion Xl | Bupropion Hcl | 14 | suppressed |
| Enbrel Sureclick | Etanercept | 14 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 14 | suppressed |
| Calcitriol | Calcitriol | 13 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 13 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Ibu | Ibuprofen | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 12 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 12 | suppressed |
| Cilostazol | Cilostazol | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 11 | suppressed |
| Topiramate | Topiramate | 11 | suppressed |
| Trandolapril | Trandolapril | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $371.90 · 16 records | Novartis Pharmaceuticals Corporation | ABRYSVO, COMIRNATY, Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE, Kerendia, LEQVIO, MOUNJARO, PREVNAR 20, TONMYA, UBRELVY, VOQUEZNA, Wegovy, ZEPBOUND | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error